Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NVL-655
i
Other names:
NVL-655, NUV-655
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Nuvalent
Drug class:
ALK inhibitor
Related drugs:
‹
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
unecritinib (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
ZG0418 (0)
TSR-011 (0)
XZP-3621 (0)
crizotinib (312)
entrectinib (178)
alectinib (104)
lorlatinib (94)
ceritinib (67)
brigatinib (50)
ensartinib (42)
repotrectinib (27)
iruplinalkib (11)
TAE-684 (9)
SAF-189 (7)
unecritinib (6)
APG-2449 (4)
TPX-0131 (4)
envonalkib (3)
TGRX-326 (3)
AZD3463 (2)
SY-707 (1)
SY-3505 (1)
ALK inhibitor (0)
ASP-3026 (0)
CEP-37440 (0)
TY-2136b (0)
ZG0418 (0)
TSR-011 (0)
XZP-3621 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
NVL-655
Sensitive: B - Late Trials
NVL-655
Sensitive
:
B
NVL-655
Sensitive: B - Late Trials
NVL-655
Sensitive
:
B
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login